UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 111

Sortiert nach

Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study

American journal of transplantation, 2005-12, Vol.5 (12), p.2929-2936

2005

Volltextzugriff (PDF)

Therapy with the thyroid hormone receptor agonist eprotirome in patients with familial hypercholesterolemia: a randomised, double blind, placebo-controlled study

Atherosclerosis, 2014-08, Vol.235 (2), p.e12-e12

2014

Volltextzugriff (PDF)

HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin

Nutrition, metabolism, and cardiovascular diseases, 2010-10, Vol.20 (8), p.553-557

Olsson, A.G

2010

Volltextzugriff (PDF)

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. the miracl study: a randomized controlled trial

ACC current journal review, 2001-09, Vol.10 (5), p.23-23

2001

Volltextzugriff (PDF)

Lipoprotein(A) Predicts Cardiovascular Events In Statin Outcome Trials: Pooled Analysis Of Seven Randomised Controlled Trials

Atherosclerosis, 2019-08, Vol.287, p.e8-e9

2019

Volltextzugriff (PDF)

Effects of Astaxanthin Supplementation on Lipid Peroxidation

International journal for vitamin and nutrition research, 2007, Vol.77 (1), p.3-11

2007

Volltextzugriff (PDF)

84 To what LDL level should we treat the CHD patient?

Atherosclerosis, 1997-05, Vol.130, p.S22-S22

Olsson, A.G.

1997

Volltextzugriff (PDF)

Low serum β-carotene reflects immune activation in patients with coronary artery disease

Nutrition, metabolism, and cardiovascular diseases, 2003-06, Vol.13 (3), p.120-125

2003

Volltextzugriff (PDF)

Ten years experience of simvastatin treatment in marked hypercholesterolemia

Journal of the American College of Cardiology, 1998, Vol.31, p.319-319

1998

Volltextzugriff (PDF)

Familial hypercholesterolaemia and quality of life in family members

Preventive medicine, 2003-05, Vol.36 (5), p.569-574

2003

Volltextzugriff (PDF)

The new cholesterol controversy - a little bit of history repeating?

Acta Neurologica Scandinavica, 2006-01, Vol.114 (s185), p.1-2

2006

Volltextzugriff (PDF)

The role of lipids and antioxidative factors for development of atherosclerosis

The American journal of cardiology, 1993-02, Vol.71 (6), p.B15-B19

1993

Volltextzugriff (PDF)

Th-S17:1 The inventions of the ultracentrifuge and the electrophoresis - prerequisites for basic and clinical lipoprotein research

Atherosclerosis. Supplements, 2006, Vol.7 (3), p.491-491

Olsson, A.G.

2006

Volltextzugriff (PDF)

Inflammatory response in stable angina pectoris: The possible influence of statins

Atherosclerosis, 2000-07, Vol.151 (1), p.192-192

2000

Volltextzugriff (PDF)

Quality of life in genetic disease: the example of familial hypercholesterolemia

Atherosclerosis, 2000-07, Vol.151 (1), p.169-169

2000

Volltextzugriff (PDF)

Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia

Atherosclerosis, 2000-07, Vol.151 (1), p.39-39

2000

Volltextzugriff (PDF)

Fluvastatin: Extended-release vs immediate-release formulation

Atherosclerosis, 2000-07, Vol.151 (1), p.51-51

2000

Volltextzugriff (PDF)

1237: The Meaning of Quality of Life Among Patients with Familial Hypercholesterolemia

European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology, 2003-04, Vol.2 (1), p.84-84

2003

Volltextzugriff (PDF)

Effect of greater LDL-C reductions on prognosis-the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial

Atherosclerosis, 1999-05, Vol.144, p.38-38

1999

Volltextzugriff (PDF)

Effects of a-tocopherol and astaxanthin on plasma lipids, LDL oxidation and atherosclerosis in watanabe heritable hyperlipidemic rabbits

Atherosclerosis, 1999-05, Vol.144, p.56-57

1999

Volltextzugriff (PDF)

Which is the most important lipid risk factor in peripheral atherosclerosis?

Atherosclerosis, 1994-09, Vol.109 (1), p.220-221

1994

Volltextzugriff (PDF)

3.P.31 Macrophage-lysosomal enzyme relocalization and inactivation by oxidized LDL and protective effects of antioxidants

Atherosclerosis, 1997-10, Vol.134 (1-2), p.205-205

1997

Volltextzugriff (PDF)

3.P.287 Ferritin accumulation in human atheroma and its relation to apoptosis

Atherosclerosis, 1997-10, Vol.134 (1-2), p.258-258

1997

Volltextzugriff (PDF)

Predilection of atherosclerosis for the inner curvature in the femoral artery. A digitized angiography study

Arteriosclerosis, thrombosis, and vascular biology, 1995-07, Vol.15 (7), p.912

1995

Volltextzugriff (PDF)

Effect of atorvastatin and simvastatin in obtaining targets for lipids in secondary prevention. The treat-to-target study (3T)

Atherosclerosis, 2000-07, Vol.151 (1), p.46-46

2000

Volltextzugriff (PDF)

1 – 25 von 111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(102)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study

Therapy with the thyroid hormone receptor agonist eprotirome in patients with familial hypercholesterolemia: a randomised, double blind, placebo-controlled study

HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. the miracl study: a randomized controlled trial

Lipoprotein(A) Predicts Cardiovascular Events In Statin Outcome Trials: Pooled Analysis Of Seven Randomised Controlled Trials

Effects of Astaxanthin Supplementation on Lipid Peroxidation

84 To what LDL level should we treat the CHD patient?

Low serum β-carotene reflects immune activation in patients with coronary artery disease

Ten years experience of simvastatin treatment in marked hypercholesterolemia

Familial hypercholesterolaemia and quality of life in family members

The new cholesterol controversy - a little bit of history repeating?

The role of lipids and antioxidative factors for development of atherosclerosis

Th-S17:1 The inventions of the ultracentrifuge and the electrophoresis - prerequisites for basic and clinical lipoprotein research

Inflammatory response in stable angina pectoris: The possible influence of statins

Quality of life in genetic disease: the example of familial hypercholesterolemia

Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia

Fluvastatin: Extended-release vs immediate-release formulation

1237: The Meaning of Quality of Life Among Patients with Familial Hypercholesterolemia

Effect of greater LDL-C reductions on prognosis-the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial

Effects of a-tocopherol and astaxanthin on plasma lipids, LDL oxidation and atherosclerosis in watanabe heritable hyperlipidemic rabbits

Which is the most important lipid risk factor in peripheral atherosclerosis?

3.P.31 Macrophage-lysosomal enzyme relocalization and inactivation by oxidized LDL and protective effects of antioxidants

3.P.287 Ferritin accumulation in human atheroma and its relation to apoptosis

Predilection of atherosclerosis for the inner curvature in the femoral artery. A digitized angiography study

Effect of atorvastatin and simvastatin in obtaining targets for lipids in secondary prevention. The treat-to-target study (3T)

Suchergebnisse filtern